Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture
“We are delighted to make this strategic move into the oncology and molecular diagnostic spaces with the acquisition of EpiCapture,” stated John Gillard, President and Chief Executive Officer of Trinity Biotech. “This move supports our strategy of combining Trinity’s established capabilities with cutting edge technologies to address large scale, urgent and important clinical issues. In this case, our manufacturing expertise and New York State Department of Healthcertified Immco reference laboratory will enable us to advance the development and commercialization of EpiCapture’s epigenetic analysis technology, an innovative solution with the potential to significantly impact the clinical management of prostate cancer, providing a less invasive and more accurate method of monitoring disease progression.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines